Royce & Associates LP Grows Position in USANA Health Sciences, Inc. (NYSE:USNA)

Royce & Associates LP raised its position in USANA Health Sciences, Inc. (NYSE:USNA) by 17.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 38,914 shares of the company’s stock after purchasing an additional 5,771 shares during the period. Royce & Associates LP’s holdings in USANA Health Sciences were worth $1,397,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in USNA. R Squared Ltd bought a new position in shares of USANA Health Sciences during the fourth quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences during the 3rd quarter valued at $30,000. KBC Group NV grew its position in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares during the last quarter. Amundi increased its stake in USANA Health Sciences by 85.3% in the fourth quarter. Amundi now owns 4,872 shares of the company’s stock worth $170,000 after purchasing an additional 2,243 shares during the period. Finally, Centiva Capital LP bought a new stake in shares of USANA Health Sciences during the third quarter worth $213,000. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Trading Down 1.1 %

Shares of USANA Health Sciences stock opened at $27.24 on Friday. The stock’s fifty day moving average price is $31.94 and its 200-day moving average price is $35.57. The firm has a market cap of $514.92 million, a P/E ratio of 9.62, a P/E/G ratio of 0.93 and a beta of 0.98. USANA Health Sciences, Inc. has a 12 month low of $26.78 and a 12 month high of $49.78.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other news, insider David Mulham Mulham sold 3,234 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now directly owns 12,775 shares in the company, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jim Brown sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. This trade represents a 24.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,920 shares of company stock valued at $500,285 over the last ninety days. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on USNA. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Finally, DA Davidson lowered their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, February 27th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.